License Agreement Turns Biotech Partners Into Rivals
At stake is control over satraplatin, a promising prostate-cancer drug co-developed by Spectrum and its partner, GPC Biotech AG, which allegedly cut Spectrum out of $59 million worth of sublicensing deals with another German firm, Pharmion GmbH.
According to Irvine, Calif.-based Spectrum, GPC Biotech’s deal with Pharmion violated their licensing agreement, effectively ending it....
Already a subscriber? Click here to login